Entrada Therapeutics Inc (TRDA)
14.95
0.00 (0.00%)
USD |
NASDAQ |
May 20, 10:19
Entrada Therapeutics Price to Book Value: 1.874 for May 20, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.879 |
| May 16, 2024 | 1.874 |
| May 15, 2024 | 1.816 |
| May 14, 2024 | 1.778 |
| May 13, 2024 | 1.761 |
| May 10, 2024 | 1.797 |
| May 09, 2024 | 1.800 |
| May 08, 2024 | 1.761 |
| May 07, 2024 | 1.740 |
| May 06, 2024 | 1.692 |
| May 03, 2024 | 1.649 |
| May 02, 2024 | 1.699 |
| May 01, 2024 | 1.661 |
| April 30, 2024 | 1.485 |
| April 29, 2024 | 1.543 |
| April 26, 2024 | 1.557 |
| April 25, 2024 | 1.545 |
| April 24, 2024 | 1.554 |
| April 23, 2024 | 1.612 |
| April 22, 2024 | 1.638 |
| April 19, 2024 | 1.519 |
| April 18, 2024 | 1.489 |
| April 17, 2024 | 1.528 |
| April 16, 2024 | 1.590 |
| April 15, 2024 | 1.608 |
| Date | Value |
|---|---|
| April 12, 2024 | 1.616 |
| April 11, 2024 | 1.654 |
| April 10, 2024 | 1.562 |
| April 09, 2024 | 1.657 |
| April 08, 2024 | 1.678 |
| April 05, 2024 | 1.723 |
| April 04, 2024 | 1.725 |
| April 03, 2024 | 1.723 |
| April 02, 2024 | 1.732 |
| April 01, 2024 | 1.717 |
| March 31, 2024 | |
| March 28, 2024 | 1.964 |
| March 27, 2024 | 1.990 |
| March 26, 2024 | 1.908 |
| March 25, 2024 | 1.855 |
| March 22, 2024 | 1.902 |
| March 21, 2024 | 1.877 |
| March 20, 2024 | 1.851 |
| March 19, 2024 | 1.761 |
| March 18, 2024 | 1.720 |
| March 15, 2024 | 1.772 |
| March 14, 2024 | 1.691 |
| March 13, 2024 | 1.762 |
| March 12, 2024 | 1.606 |
| March 11, 2024 | 1.630 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.6208
Minimum
May 09 2022
3.069
Maximum
Oct 31 2022
1.816
Average
1.867
Median
Oct 04 2022
Price to Book Value Benchmarks
| Catalyst Pharmaceuticals Inc | 3.461 |
| Vertex Pharmaceuticals Inc | 6.201 |
| Sarepta Therapeutics Inc | 12.83 |
| PTC Therapeutics Inc | -- |
| GlycoMimetics Inc | 0.6511 |
Price to Book Value Related Metrics
| PE Ratio | 23.73 |
| PS Ratio | 3.123 |
| Price | 14.95 |
| Earnings Yield | 4.21% |
| Market Cap | 504.70M |
| Operating PE Ratio | 21.44 |
| Normalized PE Ratio | 23.73 |